Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase l, Single-blind, Placebo-controlled Trial Designed to Assess the Safety and Tolerability of a Single Intravenous Dose of MTx-COVAB36 in Healthy Volunteers.

NCT05351437 is registered in ClinicalTrials.gov with Memo Therapeutics AG as lead sponsor.

NCT NCT05351437
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05351437 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase l, Single-blind, Placebo-controlled Trial Designed to Assess the Safety and Tolerability of a Single Intravenous Dose of MTx-COVAB36 in Healthy Volunteers.
Lead sponsor
Memo Therapeutics AG
Phase
Phase 1
Overall status
Completed
Start date
April 26, 2022
Completion date
November 2, 2022
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2 infection